Research graph
References from Personalized medicine in hematology — A landmark from bench to bed. Local targets link to admitted publications; unresolved targets remain external evidence.
Discovery and saturation analysis of cancer genes across 21 tumour types
10.1038/nature12912 · 2014 · External reference
10.1038/nature12477
10.1038/nature12477 · External reference
10.1182/blood-2010-04-279083
10.1182/blood-2010-04-279083 · External reference
Characterization of aberrant pathways across human cancers
10.1186/1752-0509-7-s1-s1 · 2013 · External reference
Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk
10.1177/1947601913503341 · 2013 · External reference
10.1177/1947601913507951
10.1177/1947601913507951 · External reference
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
2013 · External reference
DNA sequencing of cancer: what have we learned?
10.1146/annurev-med-060712-200152 · 2013 · External reference
Sequencing quality assessment tools to enable data-driven informatics for high throughput genomics
10.3389/fgene.2013.00288 · 2013 · External reference
A review of post-GWAS prioritization approaches
2013 · External reference
Emerging paradigms in genomics-based crop improvements
10.1155/2013/585467 · 2013 · External reference
10.1038/nbt.2203
10.1038/nbt.2203 · External reference
10.1158/2159-8290.cd-11-0110
10.1158/2159-8290.cd-11-0110 · External reference
10.1158/2159-8290.cd-11-0184
10.1158/2159-8290.cd-11-0184 · External reference
10.1038/nature07423
10.1038/nature07423 · External reference
10.1177/1947601913486349
10.1177/1947601913486349 · External reference
c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade
10.1177/1947601913485413 · 2013 · External reference
JAK–STAT pathway and myogenic differentiation
2013 · External reference
10.18632/oncotarget.1548
10.18632/oncotarget.1548 · External reference
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
10.1182/blood-2012-07-446286 · 2013 · External reference
10.1124/jpet.105.084145
10.1124/jpet.105.084145 · External reference
Tyrosine kinase inhibitors — a review on pharmacology, metabolism and side effects
10.2174/138920009788897975 · 2009 · External reference
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
10.1056/nejm200104053441402 · 2001 · External reference
10.1038/nrc2106
10.1038/nrc2106 · External reference
10.1056/nejmra1010600
10.1056/nejmra1010600 · External reference
10.1056/nejmra1010517
10.1056/nejmra1010517 · External reference
Drug-diagnostics co-development in oncology
10.3389/fonc.2013.00315 · 2013 · External reference
New challenges and inspired answers for anticancer drug discovery and development
10.1093/jjco/hyt131 · 2013 · External reference
Meeting the technical challenges of personalized medicine and companion diagnostics
2012 · External reference
Biomarkers for determining the prognosis in chronic myelogenous leukemia
10.1186/1756-8722-6-54 · 2013 · External reference
Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib
2013 · External reference
10.1172/jci67509
10.1172/jci67509 · External reference
Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?
10.7150/thno.7445 · 2013 · External reference
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development
10.3389/fonc.2013.00313 · 2013 · External reference
10.2217/nnm.13.3
10.2217/nnm.13.3 · External reference
10.1002/jps.23773
10.1002/jps.23773 · External reference
10.1016/j.ymeth.2013.01.007
10.1016/j.ymeth.2013.01.007 · External reference
Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule
2014 · External reference
10.1371/journal.pone.0007887
10.1371/journal.pone.0007887 · External reference
10.1371/journal.pone.0024433
10.1371/journal.pone.0024433 · External reference
Landscape of genomic alterations in cervical carcinomas
2013 · External reference
The early days of DNA sequences
10.1038/85389 · 2001 · External reference
10.1073/pnas.74.12.5463
10.1073/pnas.74.12.5463 · External reference
10.1016/0022-2836(80)90196-5
10.1016/0022-2836(80)90196-5 · External reference
10.1200/jco.2012.46.5948
10.1200/jco.2012.46.5948 · External reference
10.1158/1055-9965.epi-12-1263
10.1158/1055-9965.epi-12-1263 · External reference
10.1158/1055-9965.epi-10-0044
10.1158/1055-9965.epi-10-0044 · External reference
Next generation sequencing methodologies—an overview
10.1016/b978-0-12-394287-6.00001-x · 2012 · External reference
10.1371/journal.pone.0066902
10.1371/journal.pone.0066902 · External reference
10.3390/biology1020383
10.3390/biology1020383 · External reference
10.18632/oncotarget.1537
10.18632/oncotarget.1537 · External reference
Unresolved reference
External reference
RNA-Seq technology and its application in fish transcriptomics
10.1089/omi.2013.0110 · 2013 · External reference
10.1371/journal.pcbi.1003345
10.1371/journal.pcbi.1003345 · External reference
CGAT: computational genomics analysis toolkit
10.1093/bioinformatics/btt756 · 2014 · External reference
Identification of grouped rare and common variants via penalized logistic regression
10.1002/gepi.21746 · 2013 · External reference
Realizing genomic medicine
10.1056/nejme1200749 · 2012 · External reference
10.1056/nejmra0907175
10.1056/nejmra0907175 · External reference
Clinical application of amplicon-based next-generation sequencing in cancer
2013 · External reference
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors
2014 · External reference
10.1200/jco.2009.27.4944
10.1200/jco.2009.27.4944 · External reference
Application of the ASLP technology to a novel platform for rapid and noise-free multiplexed SNP genotyping
10.1016/j.bios.2013.10.071 · 2013 · External reference
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis
10.1136/jcp.2006.040105 · 2007 · External reference
10.1146/annurev-pathol-020712-163959
10.1146/annurev-pathol-020712-163959 · External reference
10.1111/j.1365-2141.2011.08915.x
10.1111/j.1365-2141.2011.08915.x · External reference
RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease
10.1371/journal.pone.0033891 · 2012 · External reference
10.1038/ng1975
10.1038/ng1975 · External reference
10.1182/blood-2014-06-581736
10.1182/blood-2014-06-581736 · External reference
10.1038/ng.2764
10.1038/ng.2764 · External reference
Massively parallel exon capture and library-free resequencing across 16 genomes
10.1038/nmeth.f.248 · 2009 · External reference
10.1038/nbt.1583
10.1038/nbt.1583 · External reference
10.1593/neo.111252
10.1593/neo.111252 · External reference
Data acquisition, tumor heterogeneity and precision medicine: future challenges for oncologic comparative effectiveness research
10.2217/cer.12.76 · 2013 · External reference
Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status
10.1007/bf02893484 · 2007 · External reference
10.1158/1940-6207.capr-10-0234
10.1158/1940-6207.capr-10-0234 · External reference
10.1038/nrg2484
10.1038/nrg2484 · External reference
Comprehensive genomic characterization of squamous cell lung cancers. Cancer genome atlas research network
10.1038/nature11404 · 2012 · External reference
10.1073/pnas.0904720106
10.1073/pnas.0904720106 · External reference
Transcriptome-wide RNA sequencing analysis of rat skeletal muscle feed arteries. Part II: impact of exercise training in obesity
2014 · External reference
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
10.1038/ng.375 · 2009 · External reference
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up
10.1007/s12185-013-1470-1 · 2013 · External reference
Which TKI should be recommended as initial treatment for CML in chronic phase?
2012 · External reference
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders
10.1056/nejmoa0804953 · 2008 · External reference
10.1053/j.seminhematol.2013.09.006
10.1053/j.seminhematol.2013.09.006 · External reference
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
10.1038/nrc2152 · 2007 · External reference
10.2217/fon.13.62
10.2217/fon.13.62 · External reference
10.1016/j.jaad.2010.06.051
10.1016/j.jaad.2010.06.051 · External reference
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results
10.1159/000112795 · 2007 · External reference
10.1038/nrc3612
10.1038/nrc3612 · External reference
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
10.1016/j.leukres.2013.09.011 · 2014 · External reference
10.1038/nrc2559
10.1038/nrc2559 · External reference
10.4046/trd.2013.75.5.188
10.4046/trd.2013.75.5.188 · External reference
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
2013 · External reference
10.1038/nrc1434
10.1038/nrc1434 · External reference
10.1038/nrc3563
10.1038/nrc3563 · External reference
Oncogenes: direct hit on mutant RAS
10.1038/nrc3650 · 2014 · External reference
Pharmacogenomics and clinical biomarkers in drug discovery and development
2005 · External reference
Practical guidance for implementing predictive biomarkers into early phase clinical studies
10.1155/2013/891391 · 2013 · External reference
High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase
2013 · External reference
Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients
10.1177/0300060513499094 · 2013 · External reference
Pharmacogenetics of warfarin: challenges and opportunities
10.1038/jhg.2013.40 · 2013 · External reference
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method
2013 · External reference
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
10.2217/pgs.12.102 · 2012 · External reference
10.1038/nature12213
10.1038/nature12213 · External reference
10.1007/bf02893361
10.1007/bf02893361 · External reference
EGFR and VEGRFR protein expression in bone metastases of clear cell renal cancer
2007 · External reference
Cancer. Cancer cell phenotypes, in fifty shades of grey
10.1126/science.1234415 · 2013 · External reference
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management
10.1634/theoncologist.12-5-610 · 2007 · External reference
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives
10.2174/157015906776359568 · 2006 · External reference
High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses
10.1182/blood-2012-05-430140 · 2012 · External reference
10.1016/s1470-2045(05)70388-0
10.1016/s1470-2045(05)70388-0 · External reference
Erdheim–Chester: beyond the lesion
10.1182/blood-2011-01-330233 · 2011 · External reference
Multiple myeloma: destruction of Ikaros
10.1038/nrc3663 · 2013 · External reference
10.1038/nnano.2012.168
10.1038/nnano.2012.168 · External reference
10.1021/nn403370e
10.1021/nn403370e · External reference
Unresolved reference
2013 · External reference
10.1163/156856207779996931
10.1163/156856207779996931 · External reference
Recent developments in multifunctional hybrid nanoparticles: opportunities and challenges in cancer therapy
2012 · External reference
Integrated multiplatform method for in vitro quantitative assessment of cellular uptake for fluorescent polymer nanoparticles
10.1088/0957-4484/25/4/045102 · 2014 · External reference
10.2147/ijn.s596
10.2147/ijn.s596 · External reference
Gold nanoparticles: recent aspects for human toxicology
10.1186/1745-6673-8-32 · 2013 · External reference
A review of mammalian toxicity of ZnO nanoparticles
10.2147/nsa.s23932 · 2012 · External reference
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles
10.1038/srep03313 · 2013 · External reference
10.1517/17425247.2010.538679
10.1517/17425247.2010.538679 · External reference
Synthesis of surfactant free PCL–PEG brushed nanoparticles with tunable degradation kinetics
10.1016/j.ijpharm.2013.06.020 · 2013 · External reference
Liposome-like nanostructures for drug delivery
2013 · External reference
Toxicity evaluation of engineered nanoparticles for medical applications using pulmonary epithelial cells
2013 · External reference
10.5487/tr.2012.28.4.217
10.5487/tr.2012.28.4.217 · External reference
Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue
10.1517/17425247.5.4.459 · 2013 · External reference
The innovative medicine initiative: a public private partnership model to foster drug discovery
2013 · External reference
Current progress in structure-based rational drug design marks a new mindset in drug discovery
2013 · External reference
10.1038/nrd892
10.1038/nrd892 · External reference
